Not Yet RecruitingNCT07816315
Phase 3 Study of Intravitreal OLN324 in Adults With Neovascular (Wet) Age-related Macular Degeneration (nAMD) (OLN324-CP-04)
PHASE3 · 500 planned enrolment
- Countries listed
- 0
- Registry update
- September 11, 2026
Registry Intervention View
aflibercept
Trial registrations containing the exact intervention label aflibercept.
Exact registry label · Not reported
49 linked registrations
No aliases or equivalent products have been inferred.
Topics connected by trial metadata
18 linked registrations report posted results
This is a registry availability fact, not a safety result, comparison, or conclusion.
Understand the safety boundary →Registered trials
RecruitingNCT07496567
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
PHASE2 · PHASE3 · 960 planned enrolment
- Countries listed
- 9
- Registry update
- August 6, 2026
RecruitingNCT07317934
Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)
PHASE3 · 388 planned enrolment
- Countries listed
- 1
- Registry update
- August 6, 2026
Active Not RecruitingNCT06856577
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration
PHASE3 · 311 planned enrolment
- Countries listed
- 1
- Registry update
- May 22, 2026
Active Not RecruitingNCT06556368
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK
PHASE3 · 675 planned enrolment
- Countries listed
- 2
- Registry update
- April 29, 2026
Active Not RecruitingNCT07390253
Switch From 2mg Aflibercept to 8mg Aflibercept in Patients With Neovascular Age-related Macular Degeneration
Phase not reported · 50 planned enrolment
- Countries listed
- 1
- Registry update
- February 17, 2026
Active Not RecruitingNCT04932980
Comparison of Rapid Aflibercept and Brolucizumab T&E in wAMD
Phase not reported · 80 planned enrolment
- Countries listed
- 1
- Registry update
- December 8, 2025
CompletedNCT04270747
A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]
PHASE3 · 576 planned enrolment
- Countries listed
- 18
- Registry update
- September 10, 2025
CompletedNCT05891548
Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neovascular Age-Related Macular Degeneration
PHASE2 · 60 planned enrolment
- Countries listed
- 1
- Registry update
- July 25, 2025
CompletedNCT03823287
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)
PHASE3 · 671 planned enrolment
- Countries listed
- 15
- Registry update
- July 23, 2025
CompletedNCT03823300
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)
PHASE3 · 658 planned enrolment
- Countries listed
- 21
- Registry update
- July 11, 2025
Active Not RecruitingNCT06495918
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration
PHASE3 · 825 planned enrolment
- Countries listed
- 4
- Registry update
- June 17, 2025
Active Not RecruitingNCT06223958
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration
PHASE3 · 344 planned enrolment
- Countries listed
- 3
- Registry update
- April 18, 2025
Not Yet RecruitingNCT06839339
Efficacy and Safety of AL-001 Ophthalmic Injection in Subjects with WAMD
PHASE2 · 40 planned enrolment
- Countries listed
- 1
- Registry update
- February 21, 2025
CompletedNCT04820452
A Study of IBI302 in Patients With nAMD
PHASE2 · 231 planned enrolment
- Countries listed
- 1
- Registry update
- November 18, 2024
TerminatedNCT02387957
A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)
PHASE2 · 63 planned enrolment
- Countries listed
- 1
- Registry update
- October 30, 2024
TerminatedNCT04049266
A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.
PHASE2 · PHASE3 · 559 planned enrolment
- Countries listed
- 7
- Registry update
- July 18, 2024
CompletedNCT04964089
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)
PHASE3 · 557 planned enrolment
- Countries listed
- 2
- Registry update
- July 3, 2024
CompletedNCT05403749
A Study of Longer Interval of IVT IBI302 in Subjects With nAMD
PHASE2 · 132 planned enrolment
- Countries listed
- 1
- Registry update
- June 28, 2024
CompletedNCT04662944
A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections
Phase not reported · 494 planned enrolment
- Countries listed
- 5
- Registry update
- June 18, 2024
CompletedNCT05710471
Treatment of Recalcitrant Neovascular AMD Using Brolocizumab With Immediate T&E
PHASE4 · 30 planned enrolment
- Countries listed
- 1
- Registry update
- May 8, 2024
WithdrawnNCT05126966
A Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects With Neovascular Age-Related Macular Degeneration
PHASE3 · 0 planned enrolment
- Countries listed
- 7
- Registry update
- January 18, 2024
CompletedNCT04480463
A Study to Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD)
PHASE3 · 576 planned enrolment
- Countries listed
- 14
- Registry update
- October 10, 2023
CompletedNCT02204683
Pharmacokinetic Study of Intravitreal Aflibercept Injection in Eyes With Wet Age-related Macular Degeneration
PHASE1 · 5 planned enrolment
- Countries listed
- 1
- Registry update
- September 6, 2023
UnknownNCT05727397
Efficacy and Safety of RC28-E Versus Aflibercept
PHASE3 · 432 planned enrolment
- Countries listed
- 1
- Registry update
- August 31, 2023
CompletedNCT04126317
Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration
PHASE2 · 106 planned enrolment
- Countries listed
- 2
- Registry update
- August 14, 2023
CompletedNCT04200248
A Phase II Study of RBM-007 Alone and RBM-007 With Eylea® in Subjects With Wet Age-related Macular Degeneration
PHASE2 · 94 planned enrolment
- Countries listed
- 1
- Registry update
- June 8, 2023
TerminatedNCT03710564
Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections
PHASE3 · 535 planned enrolment
- Countries listed
- 2
- Registry update
- January 30, 2023
TerminatedNCT04684394
A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Neovascular Age-related Macular Degeneration
PHASE2 · 50 planned enrolment
- Countries listed
- 1
- Registry update
- October 31, 2022
CompletedNCT04331730
A Study to Assess the Efficacy and Safety of AKST4290 With Aflibercept in Patients With Newly Diagnosed nAMD
PHASE2 · 107 planned enrolment
- Countries listed
- 4
- Registry update
- October 26, 2022
UnknownNCT04113538
Treat and Extend Analysis Trial With Aflibercept in Wet-AMD
PHASE3 · 40 planned enrolment
- Countries listed
- 1
- Registry update
- June 14, 2022
CompletedNCT05345236
A Study to Compare QL1207 to Eylea® in Subjects With Wet Age-related Macular Degeneration (wAMD)
PHASE3 · 366 planned enrolment
- Countries listed
- 1
- Registry update
- April 25, 2022
WithdrawnNCT04919096
Study of SCB-420 in Subjects With Neovascular Age-related Macular Degeneration
PHASE1 · 0 planned enrolment
- Countries listed
- 0
- Registry update
- April 19, 2022
CompletedNCT03953079
A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD
PHASE2 · 56 planned enrolment
- Countries listed
- 1
- Registry update
- January 19, 2022
CompletedNCT05110209
Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)
Phase not reported · 331,541 planned enrolment
- Countries listed
- 1
- Registry update
- December 21, 2021
CompletedNCT05146687
Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health)
Phase not reported · 369,600 planned enrolment
- Countries listed
- 1
- Registry update
- December 16, 2021
CompletedNCT04370379
Trial to Evaluate the Safety and Tolerability of Repeated Intravitreal Injection of IBI302 in Neovascular AMD Patients
PHASE1 · 18 planned enrolment
- Countries listed
- 1
- Registry update
- November 11, 2021
TerminatedNCT03452527
Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)
PHASE2 · 15 planned enrolment
- Countries listed
- 1
- Registry update
- April 13, 2021
CompletedNCT03249740
A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular (Wet) Age-related Macular Degeneration
PHASE1 · 32 planned enrolment
- Countries listed
- 1
- Registry update
- December 20, 2019
CompletedNCT01958918
Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD
PHASE4 · 712 planned enrolment
- Countries listed
- 10
- Registry update
- March 21, 2019
CompletedNCT02401945
A Safety and Efficacy Study of DE-120 Injectable Solution for Age-related Macular Degeneration
PHASE2 · 16 planned enrolment
- Countries listed
- 1
- Registry update
- April 18, 2018
CompletedNCT02291887
Genetic Analysis of Patients Responsive to Ranibizumab But Resistant to Aflibercept
Phase not reported · 13 planned enrolment
- Countries listed
- 1
- Registry update
- November 17, 2017
CompletedNCT03313401
Effect of Aflibercept on Human Corneal Endothelial Cells in Neovascular Age-Related Macular Degeneration
Phase not reported · 34 planned enrolment
- Countries listed
- 0
- Registry update
- October 19, 2017
WithdrawnNCT02457026
Adjunctive Photodynamic Therapy + Aflibercept vs. Afilbercept Alone for PDA in NV AMD
Phase not reported · 0 planned enrolment
- Countries listed
- 1
- Registry update
- July 26, 2017
CompletedNCT02118831
Systemic Pharmacokinetics Following Intravitreal Injections of Anti-VEGF
PHASE1 · PHASE2 · 56 planned enrolment
- Countries listed
- 0
- Registry update
- May 19, 2016
CompletedNCT01950741
Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy
PHASE4 · 48 planned enrolment
- Countries listed
- 1
- Registry update
- April 29, 2016
CompletedNCT01796964
Efficacy and Safety Study of ESBA1008 Versus EYLEA®
PHASE2 · 173 planned enrolment
- Countries listed
- 0
- Registry update
- February 9, 2016
UnknownNCT01961414
Treat and Extend Therapy Study Using Intravitreal Aflibercept for Patients Exited From Protocol VGFT-OD 0910
PHASE4 · 45 planned enrolment
- Countries listed
- 1
- Registry update
- October 30, 2015
CompletedNCT01824225
Study of PRN and Every 2months Intravitreal Aflibercept for Age Related Macular Degeneration
PHASE4 · 100 planned enrolment
- Countries listed
- 1
- Registry update
- October 7, 2015